The Future of Medicine: Whole Genome Sequencing

16 Jun 2011 17:57 #1 by ScienceChic
When it becomes affordable, will you have your genome sequenced? Why or why not?

http://www.npr.org/blogs/health/2011/06 ... alif-twins
Genome Maps Solve Medical Mystery For Calif. Twins
by Richard Knox
June 16, 2011

Ever since scientists began to sequence the entire genomes of individuals —beginning with those of Nobelist James Watson and scientific entrepreneur J. Craig Venter in 2007 — skeptics have wondered just how useful this elegant and expensive trick would become.

A pair of 14-year-old twins, Alexis and Noah Beery, now provide a compelling answer, even if it's not yet clear how generalizable their case is to others with genetic disorders.

Whole-genome sequencing has enabled doctors to provide the Beery twins with a simple, highly effective treatment for a rare condition called DRD, or dopa-responsive dystonia. The tale of their cure appears in this week's issue of the journal Science Translational Medicine.


The Journal article: http://stm.sciencemag.org/content/3/87/ ... =shortener
Whole-Genome Sequencing for Optimized Patient Management
Matthew N. Bainbridge, Wojciech Wiszniewski, David R. Murdock, Jennifer Friedman, Claudia Gonzaga-Jauregui, Irene Newsham, Jeffrey G. Reid, John K. Fink, Margaret B. Morgan, Marie-Claude Gingras, Donna M. Muzny, Linh D. Hoang, Shahed Yousaf, James R. Lupski and Richard A. Gibbs
Sci Transl Med 15 June 2011:
Vol. 3, Issue 87, p. 87re3
DOI: 10.1126/scitranslmed.3002243

Whole-genome sequencing of patient DNA can facilitate diagnosis of a disease, but its potential for guiding treatment has been under-realized. We interrogated the complete genome sequences of a 14-year-old fraternal twin pair diagnosed with dopa (3,4-dihydroxyphenylalanine)–responsive dystonia (DRD; Mendelian Inheritance in Man #128230). DRD is a genetically heterogeneous and clinically complex movement disorder that is usually treated with l-dopa, a precursor of the neurotransmitter dopamine. Whole-genome sequencing identified compound heterozygous mutations in the SPR gene encoding sepiapterin reductase. Disruption of SPR causes a decrease in tetrahydrobiopterin, a cofactor required for the hydroxylase enzymes that synthesize the neurotransmitters dopamine and serotonin. Supplementation of l-dopa therapy with 5-hydroxytryptophan, a serotonin precursor, resulted in clinical improvements in both twins.


"Now, more than ever, the illusions of division threaten our very existence. We all know the truth: more connects us than separates us. But in times of crisis the wise build bridges, while the foolish build barriers. We must find a way to look after one another as if we were one single tribe.” -King T'Challa, Black Panther

The truth is incontrovertible. Malice may attack it. ignorance may deride it, but in the end, there it is. ~Winston Churchill

Please Log in or Create an account to join the conversation.

Time to create page: 0.115 seconds
Powered by Kunena Forum
sponsors
© My Mountain Town (new)
Google+